Medicare Spending Growth Won't Trigger IPAB Cost Reduction Plan
Threat of Independent Payment Advisory Board action to lower drug spending in Medicare alleviated for another year. Estimated spending growth in the program does not reach targets that would prompt cuts.
You may also be interested in...
Change, which could have multi-billion dollar impact on some large companies over 10 years, is framed as way to lower premiums in Medicare Part D.
There is a 'fair' likelihood that the Independent Payment Advisory Board will be called on to propose spending cuts to Medicare, effective in 2019, the CMS chief actuary says. And if there is no IPAB in existence, HHS will assume responsibility.
As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.